Analyst Reco. ARS Pharmaceuticals, Inc.

Equities

SPRY

US82835W1080

Market Closed - Nasdaq Other stock markets 21:00:00 29/04/2024 BST			5-day change	1st Jan Change
8.6 ^USD	+2.99%		+4.75%	+56.93%

04-18	ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	MT
04-18	ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	04-18	MT
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	04-18	MT
Ars Pharmaceuticals Insider Sold Shares Worth $927,735, According to a Recent SEC Filing	04-10	MT
Leerink Partners Upgrades ARS Pharmaceuticals to Outperform From Market Perform, Raises Price Target to $18 From $6	03-05	MT
William Blair Upgrades ARS Pharmaceuticals to Outperform From Market Perform	02-20	MT
Wedbush Raises ARS Pharmaceuticals' PT to $19 From $13 After Model Adjustments, Keeps Outperform Rating	02-06	MT
Wedbush Raises ARS Pharmaceuticals' PT to $13 From $5, Says Market Opportunity Intact; Maintains Outperform Rating	11-13	MT
Wall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Rates	20/09/23	MT
US Futures Rise Modestly Pre-Bell as Investors Await Fed Rate Decision	20/09/23	MT
Rate Hike Pause Hopes Boost Exchange-Traded Funds, Equity Futures Premarket Wednesday	20/09/23	MT
William Blair Downgrades ARS Pharmaceuticals to Market Perform From Outperform	20/09/23	MT
Wedbush Trims ARS Pharmaceuticals' PT to $15 From $17, Adjusts US, EU Launch Estimates, Lowers Peak Penetration for neffy/Anaphylaxis in US; Keeps Outperform Rating	21/06/23	MT
Wedbush Initiates ARS Pharmaceuticals at Outperform With $10 PT, Says Neffy Intranasal Spray Set to Shake Up Epinephrine Market	31/01/23	MT
William Blair Initiates ARS Pharmaceuticals With Outperform	04/01/23	MT
SVB Securities Initiates ARS Pharmaceuticals With Outperform Rating, Price Target is $14	13/12/22	MT
Stifel Adjusts Price Target on Silverback Therapeutics to $5 From $6, Reiterates Hold Rating	16/05/22	MT
Goldman Sachs Downgrades Silverback Therapeutics to Neutral From Buy, Adjusts Price Target to $3.50 From $25	04/04/22	MT
JonesTrading Downgrades Silverback Therapeutics to Hold From Buy	01/04/22	MT
SVB Leerink Downgrades Silverback Therapeutics to Market Perform from Outperform, Adjusts Price Target to $1.80 from $25	01/04/22	MT
HC Wainwright Downgrades Silverback Therapeutics to Neutral from Buy	01/04/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. ARS Pharmaceuticals, Inc.

Equities

SPRY

US82835W1080

Analyst Reco.

Filters